N@N

Dyax Corp. to Present at June 2010 Investor Conferences

_{//health-fitness.news-articles.net/content/2010/ .. o-present-at-june-2010-investor-conferences.html}
^{Published in Health and Fitness on Wednesday, June 2nd 2010 at 16:40 GMT by Market Wire}  

CAMBRIDGE, Mass.--([ BUSINESS WIRE ])--Dyax Corp. (NASDAQ:DYAX), a developer of novel biotherapeutics for unmet medical needs, announced today that company management of Dyax will present at three investor conferences in June:

• George Migausky, Executive Vice President and Chief Financial Officer, will present on Wednesday, June 9^th at 9:20 AM (ET) at the 9^th Annual Needham Healthcare Conference being held June 9-10^th at The New York Palace Hotel in New York City.
• Gustav Christensen, President and Chief Executive Officer, will present on Thursday, June 10^th at 1:00 PM (ET) at the Jefferies 2010 Global Life Sciences Conference being held June 8-11^th at the Grand Hyatt in New York City.
• George Migausky, Executive Vice President and Chief Financial Officer, will present on Wednesday, June 16^th at 4:00 PM (ET) at the ThinkEquity Mid Year Check-Up on Healthcare Conference being held June 16^th at the Princeton Club in New York City.

The Dyax presentations will be webcast live and may be accessed by visiting the Investor Relations section of the company website at [ www.dyax.com ]. The webcasts will also be available on the Dyax website for a limited period of time following the conferences.

About Dyax

Dyax is a fully integrated biopharmaceutical company focused on discovering, developing and commercializing novel biotherapeutics for unmet medical needs. Dyax utilizes its proprietary drug discovery technology to identify antibody, small protein and peptide compounds for clinical development. Our lead product, DX-88, has been approved under the brand name KALBITOR^® (ecallantide) in the United States for the treatment of acute attacks of hereditary angioedema in patients 16 years of age and older.

In addition to its approved commercial use, DX-88 is also being evaluated for its therapeutic potential in other angioedema indications (acquired and ACE inhibitor-induced angioedemas) and, through a collaboration with Fovea Pharmaceuticals (a subsidiary of sanofi aventis), is in a Phase 1 trial for retinal vein occlusion-induced macular edema.

DX-88 and other compounds in Dyaxa™s pipeline were identified using its patented phage display technology, which rapidly selects compounds that bind with high affinity and specificity to therapeutic targets. Dyax leverages this technology broadly with over 70 revenue generating licenses and collaborations for therapeutic discovery, as well as in non-core areas such as affinity separations, diagnostic imaging, and research reagents. Dyax is headquartered in Cambridge, Massachusetts. For online information about Dyax Corp., please visit [ www.dyax.com ].